Literature DB >> 7937865

A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.

T Moriai1, M S Kobrin, C Hope, L Speck, M Korc.   

Abstract

Epidermal growth factor (EGF) and type alpha transforming growth factor (TGF-alpha) bind to a specific region in subdomain III of the extracellular portion of the EGF receptor (EGFR). Binding leads to receptor dimerization, auto-and transphosphorylation on intracellular tyrosine residues, and activation of signal transduction pathways. We compared the binding and biological actions of EGF and TGF-alpha in Chinese hamster ovary (CHO) cells expressing either wild-type human EGFR (HER497R) or a variant EGFR that has an arginine-to-lysine substitution in the extracellular domain at codon 497 (HER497K) within subdomain IV of EGFR. Both receptors exhibited two orders of binding sites with radioiodinated EGF (125I-EGF). Similar results were obtained with 125I-TGF-alpha in cells expressing HER497R. In contrast, only one order of low-affinity binding sites was seen with 125I-TGF-alpha in the case of HER497K. Although EGF and TGF-alpha enhanced tyrosine phosphorylation of both receptors, CHO cells expressing HER497K exhibited an attenuated growth response to EGF and TGF-alpha and a reduced induction of the protooncogenes FOS, JUN, and MYC. Moreover, high concentrations of TGF-alpha (5 nM) inhibited growth in these cells but not in cells expressing HER497R. These findings indicate that a region in subdomain IV of EGFR regulates signal transduction across the cell membrane and selectively modulates that binding characteristics of TGF-alpha.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937865      PMCID: PMC44989          DOI: 10.1073/pnas.91.21.10217

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Generation of recombinant cytoplasmic domain of epidermal growth factor receptor with intrinsic protein tyrosine kinase activity.

Authors:  C Y Hsu; M Mohammadi; M Nathan; A Honegger; A Ullrich; J Schlessinger; D R Hurwitz
Journal:  Cell Growth Differ       Date:  1990-04

Review 2.  Signal transmission by the insulin-like growth factors.

Authors:  M P Czech
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

3.  Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha.

Authors:  M Korc; J E Finman
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

4.  Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells.

Authors:  A B Raitano; P Scuderi; M Korc
Journal:  Pancreas       Date:  1990-05       Impact factor: 3.327

5.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

6.  Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor.

Authors:  D G Wu; L H Wang; Y Chi; G H Sato; J D Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha.

Authors:  I Lax; A Johnson; R Howk; J Sap; F Bellot; M Winkler; A Ullrich; B Vennstrom; J Schlessinger; D Givol
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

8.  A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue.

Authors:  L A Petch; J Harris; V W Raymond; A Blasband; D C Lee; H S Earp
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

9.  Tryptic activation of the insulin receptor. Proteolytic truncation of the alpha-subunit releases the beta-subunit from inhibitory control.

Authors:  S E Shoelson; M F White; C R Kahn
Journal:  J Biol Chem       Date:  1988-04-05       Impact factor: 5.157

10.  Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor.

Authors:  M E Winkler; L O'Connor; M Winget; B Fendly
Journal:  Biochemistry       Date:  1989-07-25       Impact factor: 3.162

View more
  46 in total

1.  EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.

Authors:  A Sebio; J Salazar; D Páez; A Berenguer-Llergo; E Del Río; M Tobeña; M Martín-Richard; I Sullivan; E Targarona; J Balart; M Baiget; A Barnadas
Journal:  Pharmacogenomics J       Date:  2014-07-15       Impact factor: 3.550

2.  Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.

Authors:  Trevor McKibbin; Wei Zhao; Michael Tagen; Najat C Daw; Wayne L Furman; Lisa M McGregor; J Russell Geyer; Jeffrey W Allen; Clinton F Stewart
Journal:  Eur J Cancer       Date:  2010-06-04       Impact factor: 9.162

Review 3.  Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.

Authors:  David W Chang; Jian Gu; Xifeng Wu
Journal:  Urol Oncol       Date:  2012 Jul-Aug       Impact factor: 3.498

4.  Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

Authors:  C T Chu; K D Everiss; C J Wikstrand; S K Batra; H J Kung; D D Bigner
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

5.  Transforming growth factor-{alpha} enhances corneal epithelial cell migration by promoting EGFR recycling.

Authors:  Jennifer L McClintock; Brian P Ceresa
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-02-24       Impact factor: 4.799

6.  Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor.

Authors:  R N Jorissen; V C Epa; H R Treutlein; T P Garrett; C W Ward; A W Burgess
Journal:  Protein Sci       Date:  2000-02       Impact factor: 6.725

7.  EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Authors:  Rebecca A Mason; Elaine V Morlock; Margaret R Karagas; Karl T Kelsey; Carmen J Marsit; Alan R Schned; Angeline S Andrew
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

8.  Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.

Authors:  Cong Cao; Shan Lu; Alex Sowa; Rebecca Kivlin; Ashley Amaral; Wenming Chu; Hui Yang; Wen Di; Yinsheng Wan
Journal:  Cancer Lett       Date:  2008-04-08       Impact factor: 8.679

Review 9.  EGFR-targeted therapies in lung cancer: predictors of response and toxicity.

Authors:  Rebecca Suk Heist; David Christiani
Journal:  Pharmacogenomics       Date:  2009-01       Impact factor: 2.533

10.  Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.

Authors:  Imen Kallel; Maha Rebai; Abdelmajid Khabir; Nadir R Farid; Ahmed Rebaï
Journal:  J Biomed Biotechnol       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.